Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 102Carcinoma, Intraductal, Noninfiltrating 12Breast Carcinoma In Situ 10Ovarian Neoplasms 6Neoplasm Metastasis 6Breast Neoplasms, Male 6Neoplasms 5Glioblastoma 5Central Nervous System Neoplasms 5Prostatic Neoplasms 4Gliosarcoma 4Inflammatory Breast Neoplasms 3Glioma 3Brain Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Glioma, Subependymal 2Fallopian Tube Neoplasms 2Ependymoma 2Breast Cancer Female 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Sarcoma 1Risk Reduction Behavior 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2olaparib 1exemestane 1abemaciclib 1X-Rays 1Tamoxifen 1Letrozole 1Gonadotropin-Releasing Hormone 1Fulvestrant 1Fluorodeoxyglucose F18 1Estradiol 1Biopsy 1Anastrozole 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anatomic Stage III Breast Cancer AJCC v8 × Tamoxifen × Clear all
NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

University of Washington

Phase 2 Recruiting
60 enrolled
Breast

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡